大行評級|高盛:輕微上調友邦保險目標價至98港元 續列確信買入名單
高盛發表報吿,將友邦保險目標價由97港元輕微上調至98港元,維持“買入”評級,續列確信買入名單內,主因是看好友邦於2024年可保持強勁增長勢頭。高盛指友邦去年新業務價值(VONB)增長強勁,主要受中國香港、中國內地和泰國市場業務帶動。公司在業績簡報會上提到,內地和香港的銷售動能在2024年仍然強勁。高盛認為,這些補充資料可證明內地市場的利潤率在2023年上半年已觸底,並將在2024年持續改善。高盛又預計,友邦目前的股票回購計劃可能持續到2024年第四季,管理層未提供有關資本回報的新信息。考慮到友邦強大的資本覆蓋率和對利率變動的低敏感性,高盛認為公司有足夠的資本維持遠高於當前股息的總股東回報。報吿預計管理層將在8月時2024年上半年業績發佈會上,就股東回報將可提供更明確信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.